Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 24, Issue 6 (November 2022) 24, 643–652; 10.4103/aja2021117

LncRNA GAS5 enhances tumor stem cell-like medicated sensitivity of paclitaxel and inhibits epithelial-to-mesenchymal transition by targeting the miR-18a-5p/STK4 pathway in prostate cancer

Ting-Ting Lu1,2, Xia Tao3, Hua-Lei Li4, Ling Gai5, Hua Huang6, Feng Li1

1 Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China
2 Department of Pathology, Nantong University Medical School, Nantong 226001, China
3 Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong 226001, China
4 Department of Urology, Affiliated Hospital of Nantong University, Nantong 226001, China
5 Department of Chemotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China
6 Department of Pathology, Affiliated Hospital of Nantong University, Nantong 226001, China

Correspondence: Dr. F Li (lifeng@ntu.edu.cn)

Date of Submission 08-Jul-2021 Date of Acceptance 12-Dec-2021 Date of Web Publication 15-Mar-2022

Abstract

The onset of prostate cancer (PCa) is often hidden, and recurrence and metastasis are more likely to occur due to chemotherapy resistance. Herein, we identified downregulated long noncoding RNA (lncRNA) growth arrest-specific 5 (GAS5) in PCa that was associated with metastasis and paclitaxel resistance. GAS5 acted as a tumor suppressor in suppressing the proliferation and metastasis of paclitaxel-resistant PCa cells. GAS5 overexpression in vivo inhibited the tumor growth of xenografts and elevated PCa sensitivity to paclitaxel. Combination of GAS5 and paclitaxel treatment showed great potential in PCa treatment. Moreover, mechanistic analysis revealed a novel regulatory network of GAS5/miR-18a-5p/serine/threonine kinase 4 (STK4) that inhibits epithelial-to-mesenchymal transition (EMT) and enhances tumor stem cell-like-mediated sensitivity to paclitaxel in PCa. These findings provide a novel direction for the development of a potential adjunct to cancer chemotherapy that aims to improve the sensitivity of chemotherapy drugs in PCa.

Keywords: epithelial-to-mesenchymal transition; growth arrest-specific 5; long noncoding RNA; paclitaxel; prostate cancer

Full Text | PDF |

 
Browse:  330
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.